Moderna, Inc. (MRNA)
Overview
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Explore More Data
Key Information
Stock Snapshot (Updated: Nov 05 04:00 PM EST)
Capital Structure (Updated: Nov 05 04:00 PM EST)
Calendar Events (Upcoming Earnings & Revenue Forecasts)
| Earnings | |
| Earnings Date | 2025-11-06 |
| Earnings Call | 2025-11-06 |
| Avg EPS Estimate | -2.1627 |
| Low EPS Estimate | -3.1 |
| High EPS Estimate | -1.31 |
| Revenue | |
| Avg Revenue Forecast | 869,887,640 |
| Low Revenue Forecast | 610,943,180 |
| High Revenue Forecast | 1,431,100,000 |
MRNA Liquidity Indicators Shows key metrics that reflect cash availability and short-term payment ability
| Field | Value | Description |
|---|---|---|
| Cash Holdings | $5,130,999,808 | Cash on hand, which directly shows a company's ability to meet short-term obligations. |
| Quick Ratio | 3.555 | The quick ratio, which excludes inventory, measures short-term solvency; a value above 1 is considered relatively safe. |
| Current Ratio | 3.926 | The current ratio, calculated as current assets divided by current liabilities; the higher the value, the better the liquidity. |
| Total Debt | $741,000,000 | Total liabilities, used together with cash and liquidity ratios to assess debt burden. |
MRNA Profitability Indicators Shows key metrics that reflect overall earnings, margins, and core business profitability
| Field | Value | Description |
|---|---|---|
| EBITDA | $-3,064,999,936 | EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization), which measures the profitability of core operations. |
| Operating Cash Flow | $-2,696,999,936 | Operating cash flow, which reflects a company's cash-generating ability. |
| Free Cash Flow | $-2,864,375,040 | Free cash flow, after deducting capital expenditures, which can be used for dividends or reinvestment. |
| Gross Margin | -71.44% | Gross margin; a higher value indicates stronger product profitability. |
| Operating Margin | -638.73% | Operating margin; slightly negative, indicating high operating costs. |
| Profit Margin | -94.31% | Net profit margin, which reflects overall profitability. |
MRNA Leverage & Financial Health Indicators Shows key metrics that reflect debt levels, liquidity, and overall financial stability
| Field | Value | Description |
|---|---|---|
| Debt/Equity Ratio | 7.88% | Low leverage level, indicating the company has low debt pressure. |
| Total Debt | $741,000,000 | Used together with cash and EBITDA to assess debt-paying ability. |
MRNA Growth Indicators Shows key financial metrics that reflect profitability, cash flow, and business expansion
| Field | Value | Description |
|---|---|---|
| Revenue Growth (YoY) | -41.10% | Rapid revenue growth, indicating fast business expansion. |
| Earnings Growth (YoY) | 0.00% | Significant EPS growth, indicating rapid improvement in profitability. |
Financial Data for MRNA (Key ratios, margins, and cash flow)
| Field | Value | Description |
|---|---|---|
| Current Price | $23.56 | Latest stock trading price |
| Price Target (High) | $178 | Analyst highest expected price |
| Price Target (Low) | $12 | Analyst lowest expected price |
| Price Target (Average) | $40.3 | Average target price across analysts |
| Price Target (Median) | $29 | Median of target prices |
| Average Rating Score | 2.88 | Average analyst rating (1=Strong Buy, 5=Sell) |
| Consensus Recommendation | hold | Consensus rating |
| Analyst Coverage Count | 20 | Number of analysts providing estimates |
| Cash Holdings | $5,130,999,808 | Total cash held by the company |
| Cash per Share | $13.19 | Cash value per outstanding share |
| Total Debt | $741,000,000 | Company's total debt |
| Quick Ratio | 3.555 | Ability to cover short-term liabilities (excludes inventory) |
| Current Ratio | 3.926 | Overall short-term liquidity |
| Debt/Equity Ratio | 7.88% | Leverage ratio: Debt / Equity |
| EBITDA | $-3,064,999,936 | Earnings before interest, taxes, depreciation & amortization |
| Total Revenue | $3,078,000,128 | Total company revenue |
| Revenue per Share | $7.974 | Total revenue divided by shares outstanding |
| Gross Profit | -71.44% | Revenue minus cost of goods sold |
| Return on Assets | -14.77% | Net income / Total assets |
| Return on Equity | -27.50% | Net income / Shareholder equity |
| Earnings Growth (YoY) | 0.00% | Year-over-year EPS growth |
| Revenue Growth (YoY) | -41.10% | Year-over-year revenue growth |
| Gross Margin | -71.44% | Gross profit / Total revenue |
| EBITDA Margin | -99.58% | EBITDA / Revenue |
| Operating Margin | -638.73% | Operating income / Revenue |
| Profit Margin | -94.31% | Net income / Revenue |
| Free Cash Flow | $-2,864,375,040 | Cash left after capital expenditures |
| Operating Cash Flow | $-2,696,999,936 | Cash from core business operations |
| Currency | USD | Reported in US dollars |
| Last Updated | 2025-11-05 | Data source from Yahoo |